Close

Pernix Therapeutics (PTX) Reports Delay in Closing Treximet Acquisition (GSK)

August 4, 2014 9:29 AM EDT Send to a Friend
Pernix Therapeutics (NASDAQ: PTX) announced that the closing of its transaction to acquire the U.S. rights to Treximet (sumatriptan ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login